Abstract
The humanized monoclonal anti-IgE antibody omalizumab is currently the only biologic drug approved for asthma treatment. Omalizumab inhibits allergic responses by binding to serum immunoglobulins E (IgE), thus preventing their interactions with cellular IgE receptors. Omalizumab is also capable of down-regulating the expression of high affinity IgE receptors on inflammatory cells, as well as the numbers of eosinophils in both peripheral blood and induced sputum. The clinical effects of omalizumab include relevant improvements in respiratory symptoms and quality of life, paralleled by a marked reduction of asthma exacerbations, emergency room visits, and use of systemic corticosteroids and rescue bronchodilators. Moreover, some recent studies suggest potential benefits of omalizumab also in non allergic phenotypes of severe asthma. Very interesting are also further recent reports referring to the potential inhibitory effect of omalizumab with regard to bronchial structural changes, especially occurring in severe asthma and globally defined as airway remodeling. Omalizumab is relatively well tolerated, and only very rarely induces anaphylactic reactions. Therefore, this drug represents a valid option as add-on therapy for patients with severe persistent asthma, inadequately controlled by high doses of standard inhaled treatments.
Keywords: Anti-IgE, omalizumab, severe asthma.
Current Drug Targets
Title:Anti-IgE Therapy with Omalizumab for Severe Asthma: Current Concepts and Potential Developments
Volume: 16 Issue: 2
Author(s): Girolamo Pelaia, Alessandro Vatrella, Maria Teresa Busceti, Luca Gallelli, Rosa Terracciano and Rosario Maselli
Affiliation:
Keywords: Anti-IgE, omalizumab, severe asthma.
Abstract: The humanized monoclonal anti-IgE antibody omalizumab is currently the only biologic drug approved for asthma treatment. Omalizumab inhibits allergic responses by binding to serum immunoglobulins E (IgE), thus preventing their interactions with cellular IgE receptors. Omalizumab is also capable of down-regulating the expression of high affinity IgE receptors on inflammatory cells, as well as the numbers of eosinophils in both peripheral blood and induced sputum. The clinical effects of omalizumab include relevant improvements in respiratory symptoms and quality of life, paralleled by a marked reduction of asthma exacerbations, emergency room visits, and use of systemic corticosteroids and rescue bronchodilators. Moreover, some recent studies suggest potential benefits of omalizumab also in non allergic phenotypes of severe asthma. Very interesting are also further recent reports referring to the potential inhibitory effect of omalizumab with regard to bronchial structural changes, especially occurring in severe asthma and globally defined as airway remodeling. Omalizumab is relatively well tolerated, and only very rarely induces anaphylactic reactions. Therefore, this drug represents a valid option as add-on therapy for patients with severe persistent asthma, inadequately controlled by high doses of standard inhaled treatments.
Export Options
About this article
Cite this article as:
Pelaia Girolamo, Vatrella Alessandro, Teresa Busceti Maria, Gallelli Luca, Terracciano Rosa and Maselli Rosario, Anti-IgE Therapy with Omalizumab for Severe Asthma: Current Concepts and Potential Developments, Current Drug Targets 2015; 16 (2) . https://dx.doi.org/10.2174/1389450116666141219122157
DOI https://dx.doi.org/10.2174/1389450116666141219122157 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Probiotic Research in Australia, New Zealand and the Asia-Pacific Region
Current Pharmaceutical Design Synthesis and Evaluation of Indole Based Molecules for Treatment of Oxidative Stress Related Diseases
Current Topics in Medicinal Chemistry Cholinergic Drugs as Therapeutic Tools in Inflammatory Diseases: Participation of Neuronal and Non-Neuronal Cholinergic Systems.
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Development of Anti-Atherosclerosis Therapy Based on the Inflammatory and Proliferative Aspects of the Disease
Current Pharmaceutical Design Electrochemical Immunosensors for Disease Detection and Diagnosis
Current Medicinal Chemistry Antimicrobial Activity of Oleiyl Glucoside Isolated from the Traditional Medicinal Plant, Capparis decidua
The Natural Products Journal Anxiety: A Systematic Review of Neurobiology, Traditional Pharmaceuticals and Novel Alternatives from Medicinal Plants
CNS & Neurological Disorders - Drug Targets Systemic Approach to the Study of Complex Bone Disorders at the Whole- Genome Level
Current Genomics Increased Neuronal Injury in Clock Gene Per-1 Deficient-Mice after Cerebral Ischemia
Current Neurovascular Research Complementary and Alternative Medical Therapies in Fibromyalgia
Current Pharmaceutical Design Aquaporin-1 and Sodium-Hydrogen Exchangers as Pharmacological Targets in Diabetic Atherosclerosis
Current Drug Targets Vasoactive Intestinal Peptide Receptors: A Molecular Target in Breast and Lung Cancer
Current Pharmaceutical Design Leptin and Inflammation
Current Immunology Reviews (Discontinued) Therapeutic Utility and Medicinal Chemistry of Cathepsin C Inhibitors
Current Topics in Medicinal Chemistry Adenosine Receptor Ligands in Clinical Trials
Current Topics in Medicinal Chemistry Ocular Application of Macrobiomolecules in Anti-Allergy and Anti- Inflammation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Relevance of Pharmacokinetics and Bioavailability of Intranasal Corticosteroids in Allergic Rhinitis
Recent Patents on Inflammation & Allergy Drug Discovery The Anti-Inflammatory Role of Annexin-1 in Arthritis
Current Rheumatology Reviews Clinical Implications of Macrolide Therapy in Chronic Sinopulmonary Diseases
Current Pharmaceutical Design Epitope Peptides and Immunotherapy
Current Protein & Peptide Science